Pathos becomes paid operating partner
Pathos
The key shift is that Pathos can monetize oncology intelligence without first owning the drug. The AstraZeneca and Tempus deal shows a model where Pathos helps build the data layer and development playbook that a large pharma team can use across its own pipeline, while Pathos still keeps its separate wholly owned programs. That turns Pathos from a biotech buyer of assets into a paid operating partner for trial design, biomarker strategy, and patient selection.
-
In the April 23, 2025 collaboration, Pathos, AstraZeneca, and Tempus agreed to build a multimodal oncology foundation model, and the structure included $200M of data licensing and model development fees to Tempus over three years. That makes clear the relationship is not just about owning molecules, it is also about paying for data, models, and development infrastructure as a service.
-
This puts Pathos closer to a clinical development platform than a classic biotech. In adjacent life sciences software, Benchling built a large business by selling the system scientists use to design and track experiments, rather than owning the drugs being developed. Pathos is applying a similar logic one step later in the workflow, inside oncology trial planning and execution.
-
The regulatory backdrop makes this more valuable. FDA Project Optimus pushes sponsors to justify dose and schedule with earlier, more data rich evidence, especially for targeted drugs and combinations. That increases demand for teams that can combine biomarker data, clinical history, and simulation to choose who to enroll and how to run the study.
The next phase is Pathos selling into more programs where pharma keeps asset control but outsources the hard part of modern oncology development, which is matching the right patients, dose, and biomarker plan before a costly trial starts. If that model works, Pathos can scale revenue across many partner programs without waiting for each wholly owned drug to reach approval.